Skip to main content
Medical information Clinical review pending

Dermatology Testing

Histopathology Direct Immunofluorescence DIF Skin Conjunctival Biopsy IgA Test

A specialized test using Direct Immunofluorescence (DIF) on skin or conjunctival biopsy samples to detect IgA deposits, aiding in the diagnosis of specific skin and eye disorders.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
A skin or conjunctival biopsy specimen, minimum 3mm in size, submitted in buffered normal saline.
Results
Confirm with the laboratory before booking. Results are typically available within four working days.
Preparation
Confirm with the laboratory before booking. Ensure the biopsy is freshly collected or properly preserved and transported.
Test priceKSh 1,287

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Histopathology Direct Immunofluorescence DIF Skin Conjunctival Biopsy IgA Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Persistent skin rashes or lesions
  • ✓Eye irritation or inflammation
  • ✓Suspected autoimmune skin disorder
  • ✓Suspected autoimmune eye condition
  • ✓Unexplained skin or eye conditions
  • ✓Evaluation of blistering skin diseases
02

In plain language

What this test helps you understand

This test helps diagnose autoimmune blistering diseases and other conditions where IgA deposition in the skin or conjunctiva is suspected. It aids in differentiating between various dermatological and ophthalmological conditions.
The Histopathology Direct Immunofluorescence (DIF) Skin Conjunctival Biopsy IgA Test is a diagnostic procedure used to identify IgA-related conditions affecting the skin and eyes. This test is crucial for diagnosing various disorders and guiding treatment decisions. By analyzing biopsy specimens under fluorescence microscopy, healthcare providers can gain critical insights into the patient's condition. This test measures the presence of IgA antibodies in skin or conjunctival biopsy specimens. It is particularly useful in diagnosing autoimmune diseases and other disorders that manifest through skin and eye symptoms. Taking this test offers benefits such as accurate diagnosis, guidance for effective treatment plans, early detection of potential autoimmune conditions, and enhanced understanding of symptoms.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. Ensure the biopsy is freshly collected or properly preserved and transported.
SampleA skin or conjunctival biopsy specimen, minimum 3mm in size, submitted in buffered normal saline.
MethodologyDirect Immunofluorescence (DIF) microscopy on a biopsy specimen.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
Results depend on the quality of the biopsy specimen and the technique used. A negative result does not completely rule out all IgA-mediated conditions. Interpretation requires clinical correlation.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

A biopsy is the removal of a small piece of tissue for examination under a microscope.
IgA is an antibody. Detecting its presence in specific patterns within the tissue helps diagnose certain autoimmune conditions.
The biopsy should be transported refrigerated in buffered normal saline. Please follow specific instructions provided by the laboratory.
A positive result indicates the presence of IgA deposits in the tissue, suggesting a specific type of autoimmune or inflammatory condition. Your doctor will interpret this in context.
The biopsy procedure itself may cause discomfort, but the test analysis is painless. Discuss pain management with your doctor.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp